All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Merck opens first climate-neutral manufacturing facility in Ireland
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma
The inspection was carried out between May 26, 2025 and May 31, 2025
Subscribe To Our Newsletter & Stay Updated
